Liquiritin Attenuates Lipopolysaccharides-Induced Cardiomyocyte Injury via an AMP-Activated Protein Kinase-Dependent Signaling Pathway

• Päätekijät: Shan-Qi Mou (Tekijä), Zi-Ying Zhou (Tekijä), Hong Feng (Tekijä), Nan Zhang (Tekijä), Zheng Lin (Tekijä), Xiahenazi Aiyasiding (Tekijä), Wen-Jing Li (Tekijä), Wen Ding (Tekijä), Hai-Han Liao (Tekijä), Zhou-Yan Bian (Tekijä), Qi-Zhu Tang (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: Frontiers Media S.A., 2021-05-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Background: Liquiritin (LIQ) is a traditional Chinese medicine that has been reported to regulate inflammation, oxidative stress and cell apoptosis. However, the beneficial effects of LIQ in lipopolysaccharides (LPS)-induced septic cardiomyopathy (SCM) has not been reported. The primary goal of this...